Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brought to you by:
Allogene
Biotech
Allogene links solid tumor CAR-T to responses, deaths in phase 1
Allogene linked the off-the-shelf cell therapy to a 33% response rate but also three deaths in heavily pretreated kidney cancer patients.
Nick Paul Taylor
Nov 8, 2024 4:47am
How to get cell therapies flying off-the-shelf
May 31, 2024 9:00am
Sponsored
Allogene abandons leukemia CAR-T plans after Breyanzi approval
Nov 14, 2024 5:59am
Cell therapy reckoning: An unmet need remains in oncology
May 30, 2024 10:00am
A biotech reckoning: 'We've lost our luster in cell therapies'
May 29, 2024 10:22am
Allogene parks Notch CARs, leaving one on the road
Jan 31, 2024 10:35am
